THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 95 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2017. The put-call ratio across all filers is 28.57 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $205,377 | -16.6% | 23,798 | 0.0% | 0.00% | – |
Q2 2023 | $246,309 | -6.0% | 23,798 | -1.5% | 0.00% | – |
Q1 2023 | $262,071 | -3.3% | 24,154 | 0.0% | 0.00% | – |
Q4 2022 | $271,008 | +8.9% | 24,154 | -1.6% | 0.00% | – |
Q3 2022 | $248,836 | +9.9% | 24,540 | -1.8% | 0.00% | – |
Q2 2022 | $226,382 | -2.4% | 24,987 | +3.0% | 0.00% | – |
Q1 2022 | $231,954 | -32.8% | 24,263 | -22.3% | 0.00% | – |
Q4 2021 | $345,000 | +37.5% | 31,233 | -7.8% | 0.00% | – |
Q3 2021 | $251,000 | -42.0% | 33,873 | +13.7% | 0.00% | – |
Q2 2021 | $433,000 | -18.5% | 29,791 | +14.4% | 0.00% | – |
Q1 2021 | $531,000 | +8.4% | 26,036 | -5.6% | 0.00% | – |
Q4 2020 | $490,000 | +26.9% | 27,569 | +5.5% | 0.00% | – |
Q3 2020 | $386,000 | -29.9% | 26,133 | -2.1% | 0.00% | -100.0% |
Q2 2020 | $551,000 | -17.9% | 26,701 | -8.0% | 0.00% | 0.0% |
Q1 2020 | $671,000 | -5.4% | 29,028 | +13.2% | 0.00% | 0.0% |
Q4 2019 | $709,000 | +36.3% | 25,634 | -4.1% | 0.00% | 0.0% |
Q3 2019 | $520,000 | +17.9% | 26,742 | -1.1% | 0.00% | 0.0% |
Q2 2019 | $441,000 | -29.2% | 27,026 | -1.6% | 0.00% | 0.0% |
Q1 2019 | $623,000 | -11.0% | 27,478 | +0.5% | 0.00% | 0.0% |
Q4 2018 | $700,000 | -22.4% | 27,349 | -1.0% | 0.00% | 0.0% |
Q3 2018 | $902,000 | +26.3% | 27,613 | -12.3% | 0.00% | 0.0% |
Q2 2018 | $714,000 | -4.5% | 31,493 | +2.1% | 0.00% | 0.0% |
Q1 2018 | $748,000 | -13.4% | 30,838 | -0.4% | 0.00% | 0.0% |
Q4 2017 | $864,000 | -17.9% | 30,964 | +0.7% | 0.00% | 0.0% |
Q3 2017 | $1,053,000 | -15.4% | 30,742 | -1.5% | 0.00% | -50.0% |
Q2 2017 | $1,244,000 | +12.4% | 31,221 | +3.9% | 0.00% | +100.0% |
Q1 2017 | $1,107,000 | +35.2% | 30,046 | +17.0% | 0.00% | 0.0% |
Q4 2016 | $819,000 | -5.6% | 25,691 | +7.2% | 0.00% | 0.0% |
Q3 2016 | $868,000 | +59.9% | 23,957 | +0.2% | 0.00% | 0.0% |
Q2 2016 | $543,000 | +63.6% | 23,913 | +32.7% | 0.00% | – |
Q1 2016 | $332,000 | +21.6% | 18,025 | +8.5% | 0.00% | – |
Q4 2015 | $273,000 | +52.5% | 16,618 | +2.2% | 0.00% | – |
Q3 2015 | $179,000 | -13.9% | 16,266 | +2.0% | 0.00% | – |
Q2 2015 | $208,000 | -20.9% | 15,951 | +4.9% | 0.00% | – |
Q1 2015 | $263,000 | +20.1% | 15,201 | +3.3% | 0.00% | – |
Q4 2014 | $219,000 | -35.0% | 14,718 | +0.7% | 0.00% | – |
Q3 2014 | $337,000 | -27.5% | 14,619 | +0.3% | 0.00% | -100.0% |
Q2 2014 | $465,000 | – | 14,576 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Madison Avenue Partners, LP | 7,269,584 | $69,497,223,000 | 12.98% |
Newtyn Management, LLC | 1,375,000 | $13,145,000 | 3.15% |
Chescapmanager LLC | 1,166,574 | $11,152,000 | 1.51% |
Baupost Group | 13,643,333 | $130,430,000 | 1.40% |
Weiss Asset Management LP | 5,412,487 | $51,743,000 | 1.07% |
CM Management, LLC | 120,000 | $1,147,000 | 0.96% |
Orbimed Advisors | 3,254,713 | $31,115,000 | 0.50% |
King Wealth Management Group | 122,000 | $1,166,000 | 0.23% |
Woodline Partners LP | 1,326,653 | $12,683,000 | 0.21% |
PDT Partners, LLC | 192,701 | $1,842,000 | 0.16% |